Citing structural simplification, Pfizer announced plans to cut the company’s global staffing by about 2 percent, primarily through voluntary layoffs and early retirement through the end of 2018 and early in 2019.
German company Bayer AG is laying off 227 staffers at the company’s manufacturing plant in Berkeley, California. Most of the cuts took place on October 3, 2018.
Despite winning regulatory approval for a copycat version of Copaxone earlier in 2018, Cambridge, Mass.-based Momenta Pharmaceuticals completed a strategic review that includes slashing staff by 50 percent as the company focuses resources on two biosimilar candidates in the pipeline.
Denmark’s Novo Nordisk will cut around 250 jobs in the United States, but the drugmaker will also hire an as-yet undetermined number of staff to new positions.
Novartis will cut 2,550 jobs in Switzerland and Britain over four years as the Swiss drugmaker strives to boost profits and focus on new medicines.
Novo Nordisk said the world’s top maker of diabetes drugs will lay off 400 staff in Denmark and China as part of a broader restructuring of the company’s research and development organization.
Realm Therapeutics Slashes Staff and Explores Potential Sale as the Company Conducts a Strategic Review
Realm Therapeutics opted to discontinue all drug development programs and is considering a potential sale of the Malvern, Pa.-based company following a clinical trial failure with the atopic dermatitis treatment PR022.
Takeda Pharmaceutical will shutter the company’s Deerfield, Ill., U.S. headquarters and move the operations to Boston as the company consolidates operations following the $62 billion acquisition of Shire. The Illinois facility employs about 1,000 people.
Akcea Therapeutics Inc. planned to cut its workforce by about 10 percent after the U.S. health regulator declined to approve the company’s Waylivra drug for treating a genetic disease that causes fat accumulation in blood.
As part of an earlier announced restructuring program, UK-based GlaxoSmithKline is laying off 650 staffers in the U.S.
The Novartis Institutes for BioMedical Research is ending its early-stage anti-infectives research programs located in Emeryville, Calif. As a result, the company expects to lay off about 140 employees.
Regulus Therapeutics announced a corporate restructuring that included the termination of 60 percent of the company’s workforce, which caused a massive stock plummet.
Purdue Pharma, which sells the painkiller OxyContin, announced that the company laid off approximately 350 staffers.
Boston-based Intarcia Therapeutics undertook a restructuring that includes the termination of up to 60 employees and the closing of two programs.
Pernix Therapeutics is undergoing a reorganization that includes the termination of a number of sales representatives.
Allergan will cut 1,000 positions, about 5 percent of its workforce, as the company looks to cut costs.
Teva Pharmaceutical announced a comprehensive restructuring plan that includes the elimination of 25 percent of the company’s global workforce.
Depomed Inc. is looking to relocate its headquarters from the Bay Area after inking a deal with Collegium Pharmaceutical Inc.
Otonomy, which develops innovative therapeutics for diseases and disorders of the ear, is initiating more job cuts as well as planning to divest one of its assets.